ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)
ISSN 2383-9457 (ONLINE)
Change in medical and pharmaceutical expenditures for lung cancer by the year†
| Classification | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | CAGR |
|---|---|---|---|---|---|---|---|
| Medical expenditure | |||||||
| No. of patients (per 100,000 population) | 183 | 187 | 206 | 221 | 222 | 223 | 4.0% |
| Total | 143,397 | 156,594 | 178,002 | 230,646 | 257,151 | 254,825 | 12.2% |
| Drug prescription group | 124,444 | 135,938 | 154,791 | 201,346 | 226,545 | 229,994 | 13.1% |
| Anti-cancer drug Prescription group | 70,018 | 88,754 | 99,516 | 136,785 | 153,950 | 170,745 | 19.5% |
| Immunotherapy | - | - | 3,924 | 16,481 | 24,055 | 36,487 | 110.3% |
| Targeted therapy | 21,305 | 24,022 | 27,921 | 45,912 | 44,955 | 61,957 | 23.8% |
| Other chemotherapy | 48,714 | 64,732 | 67,671 | 74,392 | 84,940 | 72,301 | 8.2% |
| Immuno/Targeted therapy Prescription group | 21,305 | 24,022 | 31,845 | 62,393 | 69,011 | 98,444 | 35.8% |
| Pharmaceutical expenditure | |||||||
| No. of patients (per 100,000 population) | 162 | 164 | 183 | 194 | 196 | 195 | 3.8% |
| Total | 48,692 | 51,052 | 54,666 | 80,707 | 89,992 | 104,346 | 16.5% |
| Anti-cancer drug | 21,183 | 29,438 | 33,400 | 57,644 | 65,517 | 81,103 | 30.8% |
| Immunotherapy | - | - | 2,564 | 12,343 | 17,267 | 27,662 | 121.0% |
| Targeted therapy | 16,198 | 20,010 | 20,775 | 35,894 | 37,917 | 44,834 | 22.6% |
| Other chemotherapy | 4,985 | 9,428 | 10,061 | 9,408 | 10,333 | 8,608 | 11.5% |
| Immuno/Targeted therapy | 16,198 | 20,010 | 23,339 | 48,236 | 55,184 | 72,495 | 34.9% |
| Proportion to medical expenditure (%) | |||||||
| Pharmaceutical expenditure | 34.0% | 32.6% | 30.7% | 35.0% | 35.0% | 40.9% | 3.8% |
| Anti-cancer drug prescription group | 30.3% | 33.2% | 33.6% | 42.1% | 42.6% | 47.5% | 9.4% |
| Immunotherapy | - | - | 65.3% | 74.9% | 71.8% | 75.8% | 5.1% |
| Targeted therapy | 76.0% | 83.3% | 74.4% | 78.2% | 84.3% | 72.4% | -1.0% |
| Other chemotherapy | 10.2% | 14.6% | 14.9% | 12.6% | 12.2% | 11.9% | 3.1% |
| Immuno/Targeted therapy prescription group | 76.0% | 83.3% | 73.3% | 77.3% | 80.0% | 73.6% | -0.6% |
| Proportion to total pharmaceutical expenditure (%) | |||||||
| Anti-cancer drug | 43.5% | 57.7% | 61.1% | 71.4% | 72.8% | 77.7% | 12.3% |
| Proportion to total anti-cancer drug expenditure (%) | |||||||
| Immunotherapy | - | - | 7.7% | 21.4% | 26.4% | 34.1% | 64.2% |
| Targeted therapy | 76.5% | 68.0% | 62.2% | 62.3% | 57.9% | 55.3% | -6.3% |
| Other chemotherapy | 23.5% | 32.0% | 30.1% | 16.3% | 15.8% | 10.6% | -14.7% |
| Immuno/Targeted therapy | 76.5% | 68.0% | 69.9% | 83.7% | 84.2% | 89.4% | 3.2% |
*unit: costs/patients per 100,000 population, 10 thousand won, %
†Marked with ‘-’ before the introduction of reimbursements
Abbreviation: CAGR, Compound Annual Growth Rate